Traders Buy High Volume of TCR2 Therapeutics Put Options (NASDAQ:TCRR)

TCR2 Therapeutics Inc. (NASDAQ:TCRR) saw unusually large options trading activity on Wednesday. Stock investors purchased 5,849 put options on the company. This represents an increase of 1,646% compared to the typical daily volume of 335 put options.

Shares of TCRR stock traded up $0.56 during trading hours on Wednesday, hitting $17.20. The stock had a trading volume of 11,829 shares, compared to its average volume of 422,465. The firm has a market capitalization of $656.97 million, a PE ratio of -7.42 and a beta of 2.10. TCR2 Therapeutics has a twelve month low of $12.15 and a twelve month high of $35.86. The stock’s 50 day moving average is $15.01 and its 200 day moving average is $18.97.

TCR2 Therapeutics (NASDAQ:TCRR) last posted its quarterly earnings data on Thursday, August 5th. The company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.04). On average, research analysts expect that TCR2 Therapeutics will post -2.61 EPS for the current year.

A number of brokerages have issued reports on TCRR. Zacks Investment Research upgraded shares of TCR2 Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 20th. BMO Capital Markets cut their price target on shares of TCR2 Therapeutics from $53.00 to $44.00 and set an “outperform” rating on the stock in a research note on Friday, August 6th. The Goldman Sachs Group began coverage on shares of TCR2 Therapeutics in a research note on Thursday, June 24th. They set a “buy” rating and a $30.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of TCR2 Therapeutics in a research note on Friday, August 20th. Finally, SVB Leerink cut their target price on shares of TCR2 Therapeutics from $34.00 to $31.00 and set an “outperform” rating on the stock in a research note on Friday, August 6th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $39.00.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Hong Kong Ltd acquired a new stake in shares of TCR2 Therapeutics during the first quarter worth $42,000. FORA Capital LLC lifted its holdings in shares of TCR2 Therapeutics by 255.8% during the second quarter. FORA Capital LLC now owns 2,608 shares of the company’s stock worth $43,000 after purchasing an additional 1,875 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of TCR2 Therapeutics during the first quarter worth $95,000. E Fund Management Co. Ltd. acquired a new stake in shares of TCR2 Therapeutics during the first quarter worth $106,000. Finally, Royal Bank of Canada lifted its holdings in shares of TCR2 Therapeutics by 944.3% during the first quarter. Royal Bank of Canada now owns 7,383 shares of the company’s stock worth $164,000 after purchasing an additional 6,676 shares during the period. 91.77% of the stock is owned by hedge funds and other institutional investors.

About TCR2 Therapeutics

TCR2 Therapeutics, Inc is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It also involves in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development.

Featured Story: History of the Euro STOXX 50 Index

Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.